Dulaglutide Biosimilar (Beijing Shuanglu Pharmaceutical)

度拉糖肽生物类似药（北京双鹭药业）

Report date: 2026/02/06 11:44:44

Base Information

Drug NameDulaglutide Biosimilar (Beijing Shuanglu Pharmaceutical)

Drug Alias NameLong-acting Recombinant Glucagon-like Peptide-1(Beijing Shuanglu Pharmaceutical)长效重组人胰高血糖素样肽-1（北京双鹭药业）

ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionGlucagon-like peptide 1 receptor agonists

TargetsGlucagon-like peptide 1 receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusNDA/BLA

Highest Status in ChinaNDA/BLA

Originator CompaniesBeijing Sl Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sl Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A